CARLSBAD, Calif.—Life Technologies Corp. and the University of California at San Diego (UCSD) Moores Cancer Center announced Aug. 5 a partnership to use the SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia (CLL), a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers. The program aims to not only understand cancer progression, but also to identify new potential targets for possible clinical trials in support of future targeted therapies in cancer. In addition to CLL, the Moores Cancer Center research program is currently sequencing triple negative breast tumors, lung tumors and primary central nervous system lymphomas using SOLiD technology in an effort to better understand these cancers.